Skip to main content

Table 1 Descriptive Characteristics (\( \overline{X} \)±SD)

From: The effects of Shilajit supplementation on fatigue-induced decreases in muscular strength and serum hydroxyproline levels

 

Pre-Supplementation

Post-Supplementation

Total

Upper

Lower

Total

Upper

Lower

MVIC (Nm)

 Low Dose

376.1 ± 79.1

447.3 ± 45.8

311.5 ± 30.9

360.6 ± 95.3

431.9 ± 54.2

295.8 ± 76.3

 High Dose

366.0 ± 53.5

409.8 ± 44.2

326.3 ± 18.0

335.3 ± 53.0

351.6 ± 59.7

320.5 ± 43.7

 Placebo

366.3 ± 81.8

431.7 ± 60.5

306.8 ± 43.8

346.8 ± 63.6

370.4 ± 50.8

325.3 ± 68.5

% Decline MVIC

 Low Dose

16.5 ± 9.5

19.8 ± 9.1

14.1 ± 9.5

16.0 ± 12.2

18.2 ± 9.8

14.0 ± 14.1

 High Dose

14.1 ± 9.4

16.6 ± 10.8

11.8 ± 7.6

9.0 ± 6.9

9.0 ± 7.5

9.1 ± 6.6

 Placebo

13.0 ± 10.1

12.4 ± 10.0

14.2 ± 11.1

14.2 ± 6.9

14.8 ± 6.2

13.8 ± 7.8

Peak Torque (Nm)

 Low Dose

224.5 ± 49.0

267.4 ± 24.0

185.6 ± 28.0

253.0 ± 48.8

274.2 ± 28.6

233.7 ± 56.3

 High Dose

231.8 ± 42.5

266.3 ± 20.3

200.5 ± 31.1

240.2 ± 43.4

264.0 ± 31.2

218.7 ± 42.7

 Placebo

236.9 ± 56.3

283.3 ± 36.4

194.8 ± 32.1

246.1 ± 42.9

254.5 ± 43.2

238.5 ± 43.2

% Decline Peak Torque

 Low Dose

44.6 ± 15.0

46.9 ± 16.6

42.5 ± 13.8

51.5 ± 15.5

49.3 ± 15.7

53.4 ± 15.9

 High Dose

42.0 ± 16.8

41.2 ± 19.4

42.7 ± 15.0

46.5 ± 16.5

50.0 ± 13.2

43.4 ± 19.2

 Placebo

38.1 ± 18.9

42.2 ± 19.6

34.4 ± 18.3

41.2 ± 16.4

50.6 ± 15.6

39.7 ± 18.1

HYP (μg·mL− 1)

 Low Dose

2.25 ± 1.1

3.11 ± 0.9

1.48 ± 0.3

1.89 ± 0.8

2.38 ± 0.9

1.45 ± 0.5

 High Dose

2.26 ± 0.8

2.87 ± 0.9

1.70 ± 0.1

1.66 ± 0.7

1.50 ± 0.6

1.81 ± 0.8

 Placebo

2.12 ± 0.9

2.80 ± 0.8

1.50 ± 0.3

2.02 ± 0.9

2.40 ± 0.9

1.68 ± 0.6

% Change HYP

 Low Dose

9.63 ± 27.8

11.5 ± 34.0

7.2 ± 23.3

20.3 ± 70.2

5.5 ± 65.2

32.9 ± 78.9

 High Dose

15.6 ± 32.9

23.6 ± 33.8

4.8 ± 31.3

24.0 ± 62.1

39.8 ± 83.1

11.2 ± 33.2

 Placebo

17.2 ± 47.7

4.3 ± 35.7

41.1 ± 50.7

29.7 ± 92.0

0.81 ± 57.6

60.7 ± 115.7